Global Lung Cancer Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Lung Cancer Diagnostics Market Segmentation, By Product Type (Instruments, Consumables and Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2032

Lung Cancer Diagnostics Market Size

• The global lung cancer diagnostics market size was valued at USD 3.39 billion in 2024 and is expected to reach USD 9.81 billion by 2032, at a CAGR of 14.20% during the forecast period
• The market growth is largely fueled by the rising incidence of lung cancer globally, coupled with increased awareness regarding early detection and advancements in diagnostic imaging and biomarker technologies. These developments are enhancing diagnostic accuracy and enabling earlier intervention, which is critical for improving patient outcomes
• Furthermore, growing investments in precision medicine, along with increasing demand for non-invasive and rapid diagnostic methods, are establishing Lung Cancer Diagnostics as a cornerstone in oncology care. These converging factors are accelerating the adoption of advanced diagnostic tools such as liquid biopsies, low-dose CT scans, and molecular testing, thereby significantly boosting the industry's growth

Lung Cancer Diagnostics Market Analysis

• Lung Cancer Diagnostics solutions, encompassing advanced imaging modalities, biomarker tests, and biopsy procedures, are becoming indispensable tools in modern healthcare infrastructure due to their enhanced diagnostic accuracy, early detection capabilities, and compatibility with precision medicine strategies. These technologies are increasingly integrated into clinical workflows across hospitals, diagnostic labs, and cancer research institutions 
• The escalating demand for lung cancer diagnostics is primarily driven by the rising global incidence of lung cancer, growing awareness around early cancer detection, and the increasing adoption of non-invasive and personalized diagnostic tools, such as liquid biopsies and AI-based imaging analysis
• North America dominated the lung cancer diagnostics market with the largest revenue share of 47% in 2024, attributed to advanced healthcare infrastructure, high diagnostic spending, and widespread availability of cutting-edge diagnostic solutions. The U.S. significantly contributed to this dominance due to early adoption of AI-assisted imaging and genomic profiling tools, along with strong reimbursement frameworks and support from major industry players
• Asia-Pacific is expected to be the fastest growing region in the lung cancer diagnostics market during the forecast period, propelled by improving healthcare access, growing urban populations, increasing awareness about cancer screening, and rising disposable incomes, particularly in countries like China, India, and Japan
• The instruments segment dominated the lung cancer diagnostics market with a market share of 48.3% in 2024, driven by the widespread adoption of advanced diagnostic systems such as CT scanners, PET scanners, and next-generation sequencing (NGS) platforms. The increasing focus on accurate, high-throughput, and technologically advanced diagnostic equipment across hospitals and diagnostic centers continues to propel the dominance of this segment

Report Scope and Lung Cancer Diagnostics Market Segmentation   

Lung Cancer Diagnostics Market Trends

“Precision and Personalization Driving Lung Cancer Diagnostics Adoption”

• A significant and accelerating trend in the global lung cancer diagnostics market is the increasing shift toward precision medicine and personalized diagnostics, supported by advanced molecular profiling and next-generation sequencing (NGS) technologies. This evolution is significantly enhancing diagnostic accuracy, enabling tailored treatment decisions based on individual patient biomarkers

  • For instance, liquid biopsy platforms now allow non-invasive detection of circulating tumor DNA (ctDNA) and actionable mutations such as EGFR, ALK, and KRAS. These innovations are transforming how lung cancer is diagnosed, particularly in early stages and for monitoring treatment response or recurrence with minimal patient discomfort

• Modern Lung Cancer Diagnostics solutions are designed to integrate comprehensive test panels, combining imaging, genomic analysis, and histopathology to offer a full diagnostic picture. This holistic approach helps clinicians determine the most effective therapy, thereby improving patient outcomes and reducing time to treatment
• The consolidation of diagnostic capabilities into multifunctional platforms supports rapid processing and real-time decision-making in hospital and laboratory settings. Advanced diagnostic systems now provide faster turnaround times, greater test reliability, and simplified sample workflows—features highly valued by healthcare providers
• This trend toward high-throughput, accurate, and patient-friendly diagnostic systems is reshaping expectations in oncology diagnostics. As a result, companies such as QIAGEN, Guardant Health, and Biodesix are expanding their portfolios to include multi-cancer early detection and tumor profiling solutions tailored to the evolving needs of clinicians and patients
• The demand for Lung Cancer Diagnostics that offer non-invasive sampling, comprehensive biomarker analysis, and quicker results is growing rapidly across both developed and emerging markets, as healthcare systems increasingly prioritize early detection, cost-efficiency, and personalized care delivery

Lung Cancer Diagnostics Market Dynamics

Driver

“Growing Need Due to Rising Lung Cancer Incidence and Emphasis on Early Detection”

• The increasing global burden of lung cancer, coupled with heightened awareness and governmental initiatives promoting early cancer screening, is significantly driving the demand for Lung Cancer Diagnostics solutions. Early-stage detection remains critical for improving survival rates, making timely and accurate diagnostic tools a vital component of cancer care

  • For instance, in April 2024, Guardant Health announced advancements in its blood-based screening test for early-stage lung cancer, aiming to make routine screening more accessible and less invasive. Innovations like these are expected to accelerate the adoption of diagnostic solutions across both high-risk populations and routine health programs

• As healthcare providers and governments intensify efforts to reduce lung cancer mortality, Lung Cancer Diagnostics technologies such as low-dose CT scans, liquid biopsies, and biomarker-based tests offer powerful solutions that enable earlier diagnosis and facilitate targeted treatment strategies
• Furthermore, the growing demand for integrated healthcare and personalized medicine is making Lung Cancer Diagnostics an indispensable part of the clinical workflow. These systems allow physicians to better stratify patients, select appropriate therapies, and monitor disease progression—all while minimizing patient discomfort and maximizing clinical outcomes
• The convenience of non-invasive sample collection, quicker turnaround times, and the ability to conduct advanced molecular testing through minimally invasive techniques are key factors propelling the widespread adoption of Lung Cancer Diagnostics in hospitals, diagnostic laboratories, and oncology centers. In parallel, the increasing use of home-based sample collection kits and telehealth diagnostics is also expanding the reach of lung cancer testing

Restraint/Challenge

“High Costs and Limited Accessibility in Low-Resource Settings”

• Despite advancements in technology, the relatively high cost of sophisticated Lung Cancer Diagnostics—such as next-generation sequencing (NGS), molecular biomarker panels, and PET-CT imaging—remains a significant barrier to adoption, especially in low- and middle-income countries where healthcare budgets and diagnostic infrastructure are limited

  • For instance, comprehensive genomic profiling tests, while clinically valuable, often come with steep pricing and limited reimbursement coverage, making them less accessible to patients outside of advanced healthcare systems

• Moreover, the lack of widespread screening programs and trained personnel to interpret complex diagnostic results can hinder the effective deployment of these solutions in rural or underserved areas. This contributes to delayed diagnoses and poorer patient outcomes in regions with constrained healthcare access
• Addressing these challenges through public-private partnerships, expanded insurance coverage, localized manufacturing, and government-supported cancer screening initiatives will be essential for ensuring broader access. Additionally, investments in low-cost diagnostic innovations tailored for resource-limited settings will be vital to achieving equity in lung cancer care and unlocking untapped market potential

Lung Cancer Diagnostics Market Scope

The market is segmented on the basis of product type, test type, cancer type, end user, and distribution channel.

• By Product Type

On the basis of product type, the lung cancer diagnostics market is segmented into instruments, consumables, and accessories. The instruments segment accounted for the largest market revenue share of 48.3% in 2024, driven by the widespread adoption of advanced diagnostic systems such as CT scanners, PET scanners, and NGS platforms.

The consumables segment is projected to grow at the highest CAGR of 9.8% during the forecast period, fueled by increasing demand for reagents, biopsy kits, and other disposables used in routine testing and monitoring.

• By Test Type

On the basis of test type, the lung cancer diagnostics market market is segmented into biomarkers test, imaging test, biopsy, blood test, and others. The imaging test segment held the largest share of 41.6% in 2024, owing to its foundational role in lung cancer detection and staging via CT and PET imaging.

The biomarkers test segment is expected to expand at a CAGR of 10.5% during the forecast period, driven by rising adoption of molecular diagnostics, including liquid biopsy and genetic profiling.

• By Cancer Type

On the basis of cancer type, the lung cancer diagnostics market market is segmented into non-small cell lung cancer and small cell lung cancer. Non-small cell lung cancer represented the majority share, accounting for 82.4% of the total market in 2024, owing to its higher prevalence and better detection opportunities through current screening programs.

The small cell lung cancer segment is projected to grow at a CAGR of 7.4% during the forecast period, due to the increasing need for rapid diagnostics for its aggressive progression and limited treatment window.

• By End User

On the basis of end user, the lung cancer diagnostics market market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others. Hospitals dominated the market with a share of 46.7% in 2024, driven by the availability of advanced diagnostic infrastructure and integrated care.

Independent diagnostic laboratories are projected to register a CAGR of 9.2% during the forecast period, supported by expansion in specialized molecular testing and strategic partnerships.

• By Distribution Channel

On the basis of distribution channel, the lung cancer diagnostics market market is segmented into direct tender and retail sales. Direct tender accounted for 65.5% of the market share in 2024, due to procurement practices in public hospitals and large-scale health institutions.

Retail sales are expected to grow at a CAGR of 8.1%, driven by increasing adoption of at-home diagnostics and digital pharmacy platforms.

Lung Cancer Diagnostics Market Regional Analysis

• North America dominated the global lung cancer diagnostics market with a revenue share of 47% in 2024, owing to advanced healthcare infrastructure, high awareness about early cancer detection, and strong government support for cancer screening initiatives.
• The region benefits from the presence of leading diagnostics companies, growing adoption of precision medicine, and widespread insurance coverage for screening procedures.
• Increasing use of low-dose CT (LDCT) and molecular tests is further driving the market across both public and private healthcare settings

U.S. Lung Cancer Diagnostics Market Insight

The U.S. lung cancer diagnostics market captured the largest revenue share of 78% within the North American market in 2024, supported by early adoption of advanced diagnostics, such as liquid biopsies, next-generation sequencing (NGS), and imaging platforms. Public initiatives like the National Lung Screening Trial (NLST) and the availability of Medicare/Medicaid reimbursement are accelerating early detection. Rising demand for non-invasive testing and technological integration is solidifying the U.S. as the global leader in lung cancer diagnostics innovation.

Europe Lung Cancer Diagnostics Market Insight

The Europe lung cancer diagnostics market accounted for 28.6% of the market revenue in 2024 and is projected to grow at a CAGR of 7.8% from 2025 to 2032, driven by increased screening compliance, aging population, and growing demand for personalized medicine. The region benefits from strong regulatory standards, national cancer control plans, and expansion of diagnostic laboratories and cancer centers.

U.K. Lung Cancer Diagnostics Market Insight

The U.K. lung cancer diagnostics market is expected to grow at a CAGR of 8.2% from 2025 to 2032, due to ongoing investments in the NHS lung health check program, rising lung cancer prevalence, and increased use of genomic tests for targeted therapies. The focus on early detection, coupled with AI-enabled imaging and telehealth diagnostics, supports market expansion.

Germany Lung Cancer Diagnostics Market Insight

The Germany lung cancer diagnostics market held 24.3% of the European lung cancer diagnostics revenue in 2024, backed by a well-funded healthcare system, strong hospital networks, and rising focus on molecular pathology. The market is projected to grow at a CAGR of 7.5%, supported by advancements in histopathology, rapid diagnostics, and companion diagnostics integration in oncology care.

Asia-Pacific Lung Cancer Diagnostics Market Insight

The Asia-Pacific lung cancer diagnostics market is projected to register the fastest CAGR of 24% from 2025 to 2032, attributed to increasing awareness, expanding healthcare access, and rising investment in cancer diagnostics infrastructure. Countries like China, Japan, and India are experiencing rapid growth due to urbanization, increasing smoking prevalence, and growing government support for early cancer detection programs.

Japan Lung Cancer Diagnostics Market Insight

The Japan lung cancer diagnostics market accounted for 19.6% of the Asia-Pacific market share in 2024, driven by its advanced medical technology ecosystem and high uptake of smart diagnostic tools. With a high aging population and strong focus on preventive healthcare, the market is projected to grow at a CAGR of 9.4%, particularly in molecular and non-invasive diagnostic modalities.

China Lung Cancer Diagnostics Market Insight

The China lung cancer diagnostics market led the Asia-Pacific region with a market share of 38.2% in 2024, fueled by a growing middle-class population, government cancer screening programs, and rapid expansion of private diagnostic laboratories. The market is expected to grow at a CAGR of 10.7%, with a strong domestic manufacturing base and rising adoption of AI-powered imaging and blood-based diagnostics.

Lung Cancer Diagnostics Market Share

The lung cancer diagnostics industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Biodesix (U.S.)
• Amoy Diagnostics Co., Ltd. (China)
• Bio-Rad Laboratories, Inc. (U.S.)
• Biocartis (Belgium)
• Boditech Med Inc. (South Korea)
• Danaher Corporation (U.S.)
• Vela Diagnostics (Singapore)
• DiaSorin S.p.A. (Italy)
• Exact Sciences Corporation (U.K.)
• Guardant Health (U.S.)
• LalPathLabs (India)
• LungLife AI, Inc. (U.S.)
• MedGenome (India)
• Myriad Genetics, Inc. (U.S.)
• NeoGenomics Laboratories (U.S.)
• Bruker Spatial Biology, Inc. (U.S.)
• Nanoentek (South Korea)
• Oncocyte Corporation (U.S.)
• PlexBio Co. Ltd. (Taiwan)
• QIAGEN (Germany)
• Siemens Healthineers AG (Germany)
• Veracyte, Inc. (U.S.)

Latest Developments in Global Lung Cancer Diagnostics Market

• In April 2023, F. Hoffmann-La Roche Ltd. (Switzerland), a global leader in oncology diagnostics, announced the launch of an integrated diagnostic platform in South Africa to support early detection of lung cancer. The initiative aimed to expand access to molecular and imaging diagnostics in underserved regions, underscoring Roche’s commitment to improving cancer outcomes through advanced technology and global outreach
• In March 2023, Guardant Health, Inc. (U.S.) launched an updated version of its Guardant360® CDx liquid biopsy test specifically designed for detecting actionable mutations in non-small cell lung cancer (NSCLC) patients. The new assay version gained FDA approval as a companion diagnostic for multiple targeted therapies, reinforcing Guardant Health’s leadership in non-invasive cancer diagnostics
• In March 2023, Thermo Fisher Scientific Inc. successfully expanded its portfolio of lung cancer companion diagnostics by launching an NGS-based assay compatible with multiple platforms. This assay, designed for use in oncology reference labs, enables comprehensive genomic profiling of tumor samples to guide precision therapy for NSCLC patients
• In February 2023, Qiagen N.V. (Germany) partnered with several diagnostic laboratories across Asia-Pacific to introduce its QIAstat-Dx syndromic testing platform, which includes panels for detecting genetic mutations related to lung cancer. This strategic collaboration enhances Qiagen's footprint in the fast-growing APAC diagnostics market and aims to accelerate personalized treatment strategies
• In January 2023, Illumina, Inc. and Myriad Genetics, Inc. announced a strategic partnership to co-develop lung cancer-specific genomic testing workflows. The initiative focuses on simplifying NGS adoption in community hospitals and clinics by offering bundled solutions for both sequencing and data interpretation, driving broader access to lung cancer genomic profiling

SKU-55789